Dr. Neta Kela

Dr. Neta Kela

Dr. Neta Kela has more 15 years of experience in global business development and innovation and entrepreneurship education in advanced healthcare technologies. Dr. Kela has extensive experience in developing innovation and disruptive technologies in life science industry with proven clinical background in immunology, immunotherapy and drug development from the Stanford University (CA, USA) Dr. Kela holds a PhD in immunology from the Weizmann Institute of Science and won The McCormick Award from the Stanford University. Dr. Kela serves as the CEO of the Innovation accelerator and the head of Innovation and entrepreneurship program and senior faculty in SCE (engineering College) . Dr.  Kela is the author and inventor of academic papers  and serves as scientific adviser in the ScienceAbroad and ISPIM science and innovation organizations. Dr. Kela invited as an innovation expert in the Israeli media  (YNET, GLOBES, MAARIV, CHANNEL 10 and more) organizations (National Cyber Institute, Air Force, Science Abroad, Blender) and academic institute (Tel-Aviv Academic institute, McGill University)


The Entrepreneurship and Innovation Center
Head of the center
Ashdod | Be'er Sheva


Jabotinsky Campus


2008-2010       Stanford University, CA, USA. Postdoctoral fellow at the laboratory of Profs Shoshana and Ronald Levy in the Oncology department at Stanford University. The Levy lab is a leading group for cancer immunotherapy for lymphoma.
2004 - 2008     Feinberg Graduate School of the Weizmann Institute of Science, Rehovot, Israel. PhD program, Department of Immunology, in the laboratory of Prof. Avraham Ben-Nun. Ph.D title: Autoimmunity against neuronal/myelin proteins and potential contribution to the pathogenesis of Multiple Sclerosis.
2001 - 2003     Ben-Gurion University of the Negev, Beer Sheva, Israel.
M.Sc. degree, Department of Immunology and Microbiology.  Thesis topic: Identification of Salmonella typhimurium genes responsible for interference with peptide presentation on MHC class I molecules.
1998 - 2001     Ben-Gurion University of the Negev, Beer Sheva, Israel. B.Sc. degree, Faculty of Life Science


Previous research and development activities

Stanford University - Research focus: Immuno-Oncology 

Weizmann Institute – Autoimmune and Neurological disorders


Present research and development activities

Entrepreneurial intention prediction, gender and entrepreneurship

innovation diffusion, entrepreneurship education. Adoption of healthcare innovation technologies, analysis patient decision process in healthcare.


1.      Kela-Madar N., Kela I, Abittan Y. Artificial intelligence as a Growth Engine for the Healthtech Innovation Ecosystem: Business and Managerial Perspective. Submitted for publication 2019

2.      Kela-Madar N., Shmallo R. Entrepreneurship in engineering education. In preparation 2019

3.      Kela-Madar N., Katz A. Eytam E. Technology acceptance in digital health: Well-being applications. In preparation 2019

4.      Kela-Madar N., Abittan Y. The impact of innovation spillover from defense industry to multidisciplinary industries. In preparation 2019

5.      Kela-Madar N., Te'eni-Harari T, Eizekson, T. Optimism and Entrepreneurial Intentions among Students: The Mediating Role of Emotional Intelligence. Journal of Entrepreneurship Education. 22:4, Sept 2019

6.      Kela-Madar N., Kela I., "Toward Super-Creativity - Improving Creativity in Humans, Machines, and Human - Machine Collaborations." Brito S., Intechopen, July 2019

7.      Felipe Vences-Catalán, Chiung-Chi Kuo, Yael Sagi, Homer Chen, Kela-Madar N., Menno C van Zelm,Jacques J M van Dongen, Shoshana Levy. A mutation in the human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19 maturation and cell surface expression.

      J Clin Immunol 2015 Apr 6;35(3):254-63. Epub 2015 Mar 6.

8.      Shoshana Levy, Chiung-Chi Kuo, Yael Sagi, Homer Chen, Kela-Madar N., Menno van Zelm, and Jacques van Dongen . Regulation of CD19 surface expression in human B cells by CD81 (P3323). The Journal of Immunology, 2013, 190, 175.9

9.      Mizrachi K, Aricha R, Feferman T, Kela-Madar N, Mandel I, Paperna T, Miller A, Ben-Nun A, Berrih-Aknin S, Souroujon MC, Fuchs S. Involvement of phosphodiesterases in autoimmune diseases. J Neuroimmunol. 2010 Mar 30;220:43-51. Epub 2010 Jan 25.

10.    Kela-Madar N, de Rosbo NK, Ronen A, Mor F, Ben-Nun A. Autoimmune spread to myelin is associated with experimental autoimmune encephalomyelitis induced by a neuronal protein, beta-synucleinJ Neuroimmunol. 2009 Mar 31;208:19-29.
11.    Kela-Madar N., Mor F., Ronen A., Kerlero de- Rosbo N., Ben-Nun A, Mor F., Ronen A., Kerlero de- Rosbo N., Ben-Nun A. Authentication of Beta Synuclein immunogenic epitopes in HLA-transgenic mice. In preparation.
12.    Qimron U, Madar N, Mittrucker HW, Zilka A, Yosef I, Bloushtain N, Kaufmann SH, Rosenshine I, Apte RN, Porgador A. Identification of Salmonella typhimurium genes responsible for interference with peptide presentation on MHC class I molecules: Deltayej Salmonella mutants induce superior CD8+ T-cell responses. Cell Microbiol. 2004 Nov;6:1057-70.
13.    Qimron U, Madar N, Ascarelli-Goell R, Elgrably-Weiss M, Altuvia S, Porgador A. Reliable determination of transposon insertion site in prokaryotes by direct sequencing. J Microbiol Methods. 2003 Jul;54:137-40.



Strategic management


Products development

Technology innovation

From Technology to Start up